Genmab — Februar 2021
-
I wonder if Genmab i working on something like this https://www.nature.com/articles/d41586-019-03495-3
-
-
E L - therefore it looks like Roche is planning for Mosunetuzumab for first line and Glofitamab for later lines
-
and we know Jan want to put Epcoritamab in first line, and Epcoritamab is much more efficiant than Mosunetuzumab, therefore big advantage for Genmab
-
Ingen nyheder med nu +17% i Seagen https://finance.yahoo.com/quote/SGEN?p=SGEN Besynderligt...
-
Jeg sidder også og roder efter nyheder. Mon der er noget M&A hurlumhej i beggrunden?
-
...potential inclusion in s&p 500
-
Lidt anderledes end første gang GEN kom i C20 - dengang var reaktionen lodret ned og ud på røv og albuer...
-
God morgen.
-
Meg Tirrell
@megtirrellA deep dive into the effect of the Defense Production Act on a rare disease drug, Horizon’s Tepezza, for thyroid eye disease, and the impact it’s had on patients as manufacturing lines were diverted to a #covid19 vaccine https://twitter.com/megtirrell/status/1357851653152641024
-
Jan fortalte allerede for flere år siden at Jansen havde over 400 ansatte der arbejde fuld tid med dara. Det var inden den blev lanceret. Så der venter en meget kraftig stigning i antal ansatte hos genmab de næste 24 mdr (nu løfter Abb heldigvis også en stor del af det, men der kommer ikke til at gå så lang tid inden de runder 1000 ansatte)
-
de kunne bare begynde at betale udbytte
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind